For Clinicians

We believe that MEPAN is an under diagnosed condition, as MEPAN patients may be misdiagnosed with cerebral palsy, dystonia, ataxia, or even juvenile Parkisnon's Disease. MEPAN presents similarly to those conditions, and there are currently no reliable biomarkers for the disease. Patients typically have T2 hyperintensity MRI signal in the basal ganglia, and some have shown elevated levels of 3-methylglutaconic or 3-OH-isovaleric acid  acid in testing, but the only way to confirm a MEPAN diagnosis is through genetic testing. Unfortunately, the MECR gene that causes MEPAN is not yet included in many gene testing panels for movement disorders and mitochondrial disease, and we are currently conducting email outreach to introduce MECR and MEPAN to genetic testing centers in the United States and Europe.


The primary treatment recommendations for MEPAN patients are supplementation with alpha lipoic acid and medium chain triglycerides, which may help supply the octanoic acid that is a product of mtFAS and helps the body to synthesize lipoic acid needed for other biochemical processes.. Other supplements Carson and Chase have used include thiamine, riboflavin, a B-complex vitamin, vitamin C, vitamin E (with tocotrienols), N-aceytl-L-cysteine, and L-carnitine. Currently Carson and Chase are on a modified Atkins diet, which may help supply their mitochondria with ketones that can be used as an alternative energy source. More research is needed to determine if MEPAN may be suitable for advanced treatments such as enzyme replacement therapy, ASO therapy, or a gene therapy.

Please contact us at if you know of a MEPAN patient or family looking for more information.

MEPAN Foundation is a 501(c)(3) non-profit organization. Your gift is tax-deductible

EIN: 83-3594842

Privacy Policy

©2018 by